Using pro-apoptotic drugs to improve treatments for pulmonary tuberculosis
Pro-apoptotic Drugs as Host-Directed Treatments for Pulmonary Tuberculosis
['FUNDING_R01'] · JOHNS HOPKINS UNIVERSITY · NIH-11101929
This study is looking at how a drug called navitoclax can help improve treatment for people with pulmonary tuberculosis (TB) by helping to get rid of infected cells, which could lead to better lung health and shorter treatment times.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | JOHNS HOPKINS UNIVERSITY (nih funded) |
| Locations | 1 site (BALTIMORE, UNITED STATES) |
| Trial ID | NIH-11101929 on ClinicalTrials.gov |
What this research studies
This research investigates the use of pro-apoptotic drugs, specifically navitoclax, to enhance the treatment of pulmonary tuberculosis (TB). By promoting the death of infected cells, these drugs aim to reduce tissue damage and inflammation caused by TB, which can lead to chronic lung issues. The study will explore how these drugs can improve the effectiveness of existing TB treatments and prevent long-term complications associated with the disease. Patients may benefit from a shorter treatment duration and improved lung health.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with pulmonary tuberculosis who are undergoing treatment.
Not a fit: Patients with non-pulmonary forms of tuberculosis or those who have already experienced severe lung damage may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective TB treatments and better long-term lung health for patients.
How similar studies have performed: Previous research has shown promising results with similar approaches using pro-apoptotic therapies in other conditions, suggesting potential for success in this area.
Where this research is happening
BALTIMORE, UNITED STATES
- JOHNS HOPKINS UNIVERSITY — BALTIMORE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: JAIN, SANJAY — JOHNS HOPKINS UNIVERSITY
- Study coordinator: JAIN, SANJAY
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.